Multiply Labs

What Multiply Labs does

Multiply Labs, Inc. is a San Francisco-based robotics company founded in 2016 that builds physical AI systems for automated biomanufacturing of personalized pharmaceutical capsules, cell therapies, gene therapies, and biologics. Its core product, the Robotic Cluster, integrates four Universal Robots cobots with up to 24 instrument modules in under 600 square feet, automating 50+ discrete unit operations inside a closed, GMP-compliant environment. The platform's software stack includes the no-code Process Creator App, a 21 CFR Part 11 compliant manufacturing execution system, and the Resonance imitation-learning pipeline that captures process knowledge from expert video demonstrations. The company has established a broad instrument-partner ecosystem (Thermo Fisher, Cytiva, Charles River, GenScript, Wilson Wolf, Fedegari, Akron Bio, ChemoMetec, CPC Biotech) and technology partnerships with NVIDIA (Isaac, GR00T) and Universal Robots. The firm is venture-backed with approximately $41.3M raised over seven rounds, has ~52 employees, and is led by co-founders Fred Parietti (CEO) and Alice Melocchi (CSO).

The company sells its robotic cluster systems, consumables, and software via direct enterprise field sales to large pharmaceutical and biotech companies. Pricing is quote-based and structured as multi-year contracts, with deployments supported through on-site facility visits. Named enterprise customers include AstraZeneca, Legend Biotech, Kyverna Therapeutics, WuXi STA, and Stanford GMP Facility. The Italian manufacturing subsidiary (Multiply Labs Italia) was established in May 2026 in Turin to scale cluster production. Quantified performance claims include a 74% reduction in cost per dose (from $100,000 to $25,000-$35,000) and up to 100x throughput per square foot of cleanroom space relative to manual processes, with 90% of cleanroom steps automated. Revenue is not publicly disclosed, and the company is in an early-commercial phase transitioning from pilot deployments to scaled manufacturing.

Name

Multiply Labs

Legal name

Multiply Labs, Inc.

Website

https://multiplylabs.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Multiply Labs builds physical AI robotic systems that automate pharmaceutical biomanufacturing for cell therapies, gene therapies, and biologics. It sells modular Robotic Cluster systems, software, and consumables to large pharma and biotech companies.

Ownership category

akta.pro rank

Product category

Robotic Biomanufacturing Systems

NAICS

Other General Purpose Machinery Manufacturing (3339), Commercial and Service Industry Machinery Manufacturing (3333)

SIC

Special Industry Machinery, Nec (3559), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industries

Lab Automation, Instrument Control & Workflow Orchestration Software (HLAGAJAG), Collaborative Robots (Cobots) (IMAHAHAB), Robotic Process Automation (RPA) & Hyperautomation Platforms (HDAEAKAF), Robotic Process Automation (RPA) & Digital Robotics (HDAAAIAI)

Keywords

• Robotic biomanufacturing
• Cell therapy automation
• GMP-compliant robotics
• Pharmaceutical manufacturing
• Physical AI biomanufacturing

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Robotic Cluster Systems: Sale of robotic cluster systems to pharmaceutical companies for cell therapy and biologics manufacturing. The clusters are modular systems that can be configured per customer process and therapy type, with pricing likely based on configuration and throughput requirements.
2. Software and Process Control: Software licensing for process automation, real-time monitoring, and quality system integration. The Process Creator App and 21 CFR Part 11 compliant electronic records system likely generate ongoing software licensing revenue.
3. Consumables: Purpose-engineered consumables for robotic handling including G-Rex Cartridges, Cell Culture Bag Cartridges, NC-Cassette Cartridges, Syringe Cartridges, Vial Cartridges, DFP Cartridges, and Waste Bin Cartridges.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Multiply Labs builds a modular robotic biomanufacturing platform — the Robotic Cluster — that connects existing GMP instruments inside a closed, automated environment using four Universal Robots cobots operating in parallel with proprietary orchestration software. The system automates 50+ unit operations for cell therapy, gene therapy, antibody, recombinant protein, vaccine, and RNA therapy manufacturing, paired with a 21 CFR Part 11 compliant software control platform and a no-code Process Creator App. Purpose-engineered consumable cartridges support robotic handling, while the Resonance auto-training pipeline enables imitation learning from video demonstrations.

Product overview

Multiply Labs offers a modular biomanufacturing platform centered on the Robotic Cluster—a system that integrates four Universal Robots cobots operating in parallel with up to 24 instrument modules in under 600 square feet. The platform is designed to automate existing GMP instruments without process transfer or lock-in. Key components include the Process Creator App (drag-and-drop no-code process builder), Software Control Platform (21 CFR Part 11 compliant execution and monitoring), and Unit Operations Automation covering 50+ operations. Purpose-engineered Consumables support robotic handling. Advanced capabilities include NVIDIA-powered Physical AI integration (digital twins, Isaac, GR00T), Resonance auto-training pipeline for imitation learning, and real-time anomaly detection. The platform targets cell therapy, gene therapy, antibodies, recombinant proteins, vaccines, and RNA therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• Robotic Cluster Modular robotic manufacturing system packing four Universal Robots cobots and up to 24 instrument modules into under 600 square feet, connecting existing GMP instruments inside a closed, automated environment. Targets up to 100x throughput increase and 74% cost reduction per dose for cell therapy, gene therapy, and biologics manufacturing.
• Software Control Platform Manufacturing execution software that translates manufacturing protocols into robotic execution, collects every sensor reading and interaction in real time, and delivers complete 21 CFR Part 11 compliant electronic records directly to customer quality systems.
• Process Creator App (PCA) No-code, drag-and-drop interface that enables scientists to build, modify, and own their manufacturing process by visually sequencing unit operations without programming expertise.
• Consumables Portfolio Portfolio of purpose-engineered consumable cartridges designed for robotic handling, including G-Rex Cartridge, Cell Culture Bag Cartridge, NC-Cassette Cartridge, Syringe Cartridge, Vial Cartridge, DFP Cartridge, and Waste Bin Cartridge.

Quantifiable outcome

• 74% reduction in manufacturing costs per dose, from $100,000 to $25,000-$35,000
• +4 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration11 records

AI capability7 records

Feature6 records

Partnerships

Eight partnerships are on record, tiered flagship, core and minor.

• AstraZenecaflagshipStrategic or Co-development Partner · 27 January 2026Multiply Labs announced an agreement with AstraZeneca to evaluate GMP-ready robotic systems for commercial-scale cell therapy manufacturing. The collaboration focuses on end-to-end robotic automation of industry-standard instruments to enable scalable, high-throughput manufacturing while meeting clinical and commercial quality standards.
• NVIDIAcoreTechnology or Integration · 12 January 2026Multiply Labs partnered with NVIDIA to deploy physical AI robotics and simulation technologies including Isaac and GR00T into robotic biomanufacturing systems for cell and gene therapies. The collaboration uses digital twins, foundation models, and perception pipelines to increase consistency and efficiency in advanced therapy manufacturing.
• Thermo Fisher ScientificcoreStrategic or Co-development Partner · 30 September 2025Multiply Labs expanded collaboration with Thermo Fisher Scientific to integrate robotic automation with the Gibco CTS DynaCellect Magnetic Separation System. The partnership enables customers to achieve end-to-end automation in cell therapy manufacturing processes.
• Kyverna TherapeuticscoreStrategic or Co-development Partner · 12 June 2025Multiply Labs partnered with Kyverna Therapeutics to pilot robotic automation for cell therapy manufacturing. The partnership evaluates automation of Kyverna's KYV-102 CAR-T candidate manufacturing using Multiply Labs' robotic systems, aiming to reduce labor costs and increase manufacturing efficiency.
• Legend BiotechcoreStrategic or Co-development Partner · 24 September 2024Multiply Labs and Legend Biotech announced a collaboration to automate cell therapy production through robotics. Legend Biotech receives priority access to Multiply Labs' automated systems for manufacturing their CAR-T therapies including Carvykti.
• WuXi STAcoreStrategic or Co-development Partner · 1 December 2022WuXi STA and Multiply Labs partnered to deploy robotic manufacturing technology for personalized medications. The robotic system enables manufacturing of advanced solid oral dosage forms including personalized capsules with various formulation types for clinical and commercial production.
• Universal RobotscoreTechnology or IntegrationUniversal Robots provides the cobots (robotic arms) that power Multiply Labs' robotic clusters, running proprietary orchestration code for parallel operation.
• Retro BiosciencesminorStrategic or Co-development PartnerRetro Biosciences partnered with Multiply Labs for cell therapy manufacturing automation as part of their $85 million partnership for longevity research.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Others

• Universal Robots: Universal Robots is the cobot supplier whose arms power Multiply Labs' robotic cluster. It is a critical technology partner and enabling infrastructure provider rather than a direct competitor, though it could potentially expand into end-to-end biomanufacturing automation offerings.

Broad incumbents

• Lonza: Lonza is a leading CDMO with major cell and gene therapy manufacturing capacity. Lonza competes with Multiply Labs' customers in the contract manufacturing space and is also investing in automation of its own facilities, making it both a potential competitor and a potential customer.
• Cytiva: Cytiva (a Danaher company) is a major bioprocessing equipment and consumables provider that supplies instruments (Xuri bioreactor, cell processing tools) integrated with Multiply Labs' clusters. Cytiva could expand into more fully integrated automation, competing with Multiply Labs while also serving as a partner ecosystem.
• ABB: ABB is a major industrial automation and robotics company (including via its ASTI Mobile Robotics and collaborative robot offerings). ABB is a broad incumbent that could compete with Multiply Labs in pharmaceutical manufacturing automation, though its current focus is broader industrial applications.
• Thermo Fisher Scientific: Thermo Fisher Scientific provides Gibco CTS cell therapy instruments (DynaCellect, Rotea) that Multiply Labs integrates. As a dominant life sciences tools company, Thermo Fisher could develop competing end-to-end automation solutions while remaining a key instrument partner to Multiply Labs.

Direct peers

• Ori Biotech: Ori Biotech provides a fully automated cell and gene therapy manufacturing platform (Ori Cell Processing System) targeting developers of advanced therapies. Both companies are direct competitors in automating closed-system, scalable cell therapy production for clinical and commercial use.
• Cellares: Cellares is a direct competitor developing automated, closed-system cell therapy manufacturing platforms (Cell Shuttle). Both companies target cell and gene therapy manufacturers with integrated robotic bioprocessing solutions that promise higher throughput and lower cost per dose than manual methods.
• Miltenyi Biotec: Miltenyi Biotec offers the Prodigy and MACS platforms for automated cell processing and manufacturing. Both companies target cell therapy developers with integrated instrument-plus-software solutions, and Miltenyi is a competitor in the cell therapy automation niche.

Emerging players

• Cellular Origins: Cellular Origins is an early-stage UK company developing robotic, configurable cell therapy manufacturing platforms. Both companies use modular robotic systems to automate cell therapy production, with Cellular Origins focused initially on autologous cell therapy workflows.
• ScaleReady: ScaleReady offers the G-Rex-based cell therapy manufacturing platform and process development services. Both companies focus on automating and scaling cell therapy production, with ScaleReady's G-Rex cartridges integrated into Multiply Labs' consumables portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@MultiplyLabs
• LinkedInlinkedin.com/company/multiply-labs
• Xx.com/multiplylabs

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Multiply Labs